Novye preparaty dlya lecheniya ozhireniya


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

全文:

受限制的访问

作者简介

E. Ushkalova

Email: eushk@yandex.ru

参考

  1. Rueda-Clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol 2013;9(8):467-78.
  2. Heuer RD, Rosenzweig C, Steltzner A, et al. 366 days: Nature's 10. Nature 2012;492(7429):335-43.
  3. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013; 6:131-99.
  4. Morris M, Lane P, Lee K, Parks D. An integrated analysis of liver safety data from orlistat clinical trials. Obes Facts 2012;5(4):485-94.
  5. Cheung BMY, Cheung TT. Safety of Antiobesity Drugs. Ther Adv Drug Safe 2013; 4(4):171-81.
  6. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367( 1 7):1577-79.
  7. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012;36(1):13-25.
  8. Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin 2013;29(7):839-48.
  9. Arena Pharmaceuticals Press Releases, 2010. http://invest.arenapharm.com/releases.cfm.
  10. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20(7): 1426-36.
  11. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325(2):577-87.
  12. Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging 2013;6(4):560-67.
  13. Shram MJ, Schoedel KA, Bartlett C, et al. Abuse potential assessment of lorcaserin, a selective and potent agonist at the serotonin 2C (5-HT2C) receptor, in healthy male and female recreational polydrug users. Clin Pharmacol Ther 2010;87:S1.
  14. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 2012;36(1):13-25.
  15. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting antiobesity drugs? Neuropharmacology. 2012;63( 1 ):132-46.
  16. VI-0521 (QNEXA®) ADVISORY COMMITTEE BRIEFING DOCUMENT. NDA 022580 Endocrinologic and Metabolic Drugs Advisory CommitteeMeetingJuly15,2010http://www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisory Committee/ U CM218821.pdf
  17. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71 (4):272-76.
  18. Lisa Nainggolan. New Obesity Drug, Belviq, in US Pharmacies Next Week. Medscape. Jun 07, 2013.
  19. Refusal of the marketing authorisation for Qsiva (phentermine / topiramate) EMA/666052/2012. www.ema.europa. eu/docs/en_GB/document_library/../ WC500134085.pdf
  20. Lam DD, Przydzial MJ, Ridley SH, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 2008;149:1323-28.
  21. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-56.
  22. Fidler MC, Sanchez M, Raether B, et al.; BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067-77.
  23. Chan EW, He Y, Chui CS, Wong AY, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 2013; 14(5):383-92.
  24. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989;2:1142-45.
  25. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 -year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
  26. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72.
  27. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J Am Med Assoc 2006;295:761-75.
  28. Apfelbaum M, Vague P, Ziegler, O, et al. Longterm maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106:179-84.
  29. JamesWP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356: 2119-25.
  30. Fleming JW, McClendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/ topiramate. Ann Pharmacother 2013;47(7-8):1007-16.
  31. Gallwitz B. Novel Oral Anti-Obesity Agents: New Perspectives with Lorcaserin? Drugs 2013;73:393-95.
  32. Eisai Inc. Belviq (lorcaserin hydrochloride) tablets, for oral use. 2012. http://www. accessdata.fda.gov/drugsatfda_docs/ label/2012/022529lbl.pdf.
  33. Fiedorowicz JG, Miller DD, Bishop JR, et al. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev 2012;8( 1 ):25-36.
  34. Antel J, Hebebrand J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Handb Exp Pharmacol 2012;(209):433-66.
  35. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16(10):961-66.
  36. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat dose ranging study group. Eur J Clin Pharmacol 1999;54:125-32.
  37. D spres JP, Golay A, Sjostrom L. Rimonabant. In: Obesity Lipids Study Group (Ed.), Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia. N Engl J Med 2005;353:2121-34.
  38. Smith SM, Meyer M, Trinkley KE. Phentermine/ topiramate for the treatment of obesity. Ann Pharmacother 2013;47(3):340-49.
  39. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95(2):297-308.
  40. Berlie HD, Hurren KM. Evaluation of lorcaserin for the treatment of obesity. Expert Opin Drug Metab Toxicol 2013;9(8):1053-59.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##